OLMA News and Press, Olema Pharmaceuticals Inc. From 04/03/24

2024-04-03 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-28 17:59:49 ET Summary OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer. Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-po...

2024-03-24 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 16:54:52 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Oral SERD Developer With Interesting Data Seeking Alpha’s Quant Rating on Olema Pharmaceuticals Historical earnings data for Olema Pharmaceuticals Financial information for Ole...

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 2026 60-patient Phase 2 stud...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250) Pre-clinical results demonstrate that palazestrant, as both a CERAN and a SERD, has a highly differentiated mechanism of acti...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's c...

2024-01-31 16:31:02 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Oral SERD Developer With Interesting Data Olema Pharmaceuticals: Advancing On Multiple Fronts Read the full article on Seeking Alpha For further details see: Olema Pharmaceuticals...

2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group  ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus,  ( EOLS ) +2% . SSR Mining  ( SSRM ) +2% . Losers: Progress Software ...